To address these challenges, we developed a Markov cohort state-transition model to compare the cost-utility of various PCSK9 inhibitor regimens combined with statins for Chinese patients with hypercholesterolemia or at high cardiovascular risk. The gene discussed is PCSK9; the disease is familial hypercholesterolemia.